Table 1.
Demographics and baseline clinical characteristics
| Characteristic | Placebo (n = 27) | Fezolinetant 60 mg (n = 23) | Fezolinetant 180 mg (n = 23) |
|---|---|---|---|
| Age, median (range), y | 27.0 (18-44) | 27.0 (21-41) | 26.0 (19-34) |
| Ht, median (range), cm | 166 (158-177) | 170 (157-178) | 170 (159-186) |
| Wt, median (range), kg | 84.7 (51.7-137.7) | 75.0 (61.0-125.4) | 80.0 (52.3-126.0) |
| BMI, median (range) | 31.2 (17.1-50.0) | 26.7 (19.5-42.0) | 26.6 (20.5-43.6) |
| Race, n (%) | |||
| White | 22 (81.5) | 16 (69.6) | 17 (73.9) |
| Black | 1 (3.7) | 0 (0) | 1 (4.3) |
| Asian | 0 (0) | 1 (4.3) | 0 (0) |
| American Indian/Alaskan native | 0 (0) | 1 (4.3) | 0 (0) |
| Not askeda | 4 (14.8) | 5 (21.7) | 5 (21.7) |
| Ethnicity, n (%) | |||
| Hispanic/Latino | 0 (0) | 1 (4.3) | 0 (0) |
| Not Hispanic/Latino | 26 (96.3) | 21 (91.3) | 22 (95.7) |
| Not askeda | 1 (3.7) | 1 (4.3) | 1 (4.3) |
Abbreviation: BMI, body mass index.
a Local regulations restricted asking.